Riboway Therapeutics is pioneering RNA-targeted therapeutics using an AI-driven platform that decodes RNA regulation to precisely control protein expression—upregulation, downregulation, activation, or inhibition. We’re the first to activate undruggable proteins via RNA-targeting, opening new treatment paths for diseases with no cures. Our lead program targets the root cause of a monogenic neurodegenerative disease, with a development candidate aiming for clinical PoC in three years. With successful validation across 5/5 targets, we’re unlocking the next generation of RNA medicines.